Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2015 > Volume 24 Number 2 March 2015 > LIBMAN-SACKS ENDOCARDITIS > Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome Undergoing Cardiac Valve Surgery

Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome Undergoing Cardiac Valve Surgery

Rawa Arif, Mina Farag, Philipp Seppelt, Carsten J. Beller, Arjang Ruhparwar, Matthias Karck, Klaus Kallenbach

Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany

Background and aim of the study: Systemic lupus erythematosus (SLE) and primary/secondary antiphospholipid syndrome (APLS) may cause early degenerative changes in cardiac valves, such as Libman-Sacks endocarditis, though few reports exist of this condition. Herein are presented the early and late clinical outcomes after cardiac valve surgery in patients diagnosed with SLE and APLS in a single-center experience.

Methods: A prospective analysis was conducted of the perioperative and follow up data acquired from patients with diagnosed SLE, and primary and secondary APLS, who underwent either single or combined valve surgery at the authors’ department between 2002 and 2014.

Results: Fifteen patients (14 females, one male; mean age 53 ± 16 years; range: 16-77 years) were identified. The mean follow up time was 49 ± 32 months (range: 12.5-119 months). Thirteen patients (11 females, two males) were


diagnosed with SLE; one of these patients had tricuspid Libman-Sacks endocarditis, while two female patients had primary APLS and four had secondary APLS. Besides bioprosthetic and mechanical valve replacements, mitral and tricuspid valve reconstruction were performed. The mean cross-clamp time was 112 ± 73 min (range: 55-294 min). Early major cardiovascular events occurred in two patients, and late non-fatal events in four patients, including one thromboembolic event. The 30-day and in-hospital mortalities were both 0%. Currently, 12 patients (80%) are alive at the end of follow up. Actuarial survival was 92 ± 7.4% at one year, 74 ± 18% at four years, and 49 ± 23% at ten years.

Conclusion: Despite general concerns, the present results confirmed that patients with SLE and APLS can be operated on for cardiac valve disease, with favorable early results and acceptable long-term outcome.

The Journal of Heart Valve Disease 2015;24:228-235


Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome Undergoing Cardiac Valve Surgery

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.